Download Hospital X Is Among First Hospitals in U

[Institution] First in [insert city/province/country] to Treat Atrial Fibrillation
Patients with Unique, Second-Generation Freezing Technology
Arctic Front Advance™ Cardiac Cryoballoon System Provides Efficient Approach to
Treating Common Heart Rhythm Disorder
Physicians at [insert institution] are among the first in [insert
state/province/country] to treat patients who suffer from a common form of atrial
fibrillation with the new Arctic Front Advance™ Cardiac Cryoballoon System.
This innovative medical technology works by freezing the heart tissue around
the pulmonary veins to help stop abnormal electrical activity that causes an
irregular heartbeat.
The first-generation Arctic Front® Cardiac CryoAblation System, currently
approved in both the United States and Europe, has become successful treatment
option for patients who do not respond to therapy with antiarrhythmic drugs,
such as beta blockers. Studies show that 73 percent of patients using Medtronic’s
cryoballoon achieved freedom from atrial fibrillation at one year1, 2, a clinically
significant increase in overall treatment success compared to drug therapy.3
Arctic Front Advance, the second-generation cryoballoon, builds upon the
proven safety and effectiveness of the original technology, while providing a
more efficient approach to treating this common, often debilitating condition.
Treatment with Arctic Front Advance involves a minimally invasive procedure
that isolates the pulmonary veins using coolant rather than heat. Delivered
through a catheter, the novel technology is associated with faster procedure
times than other ablation techniques currently on the market. Additionally, the
EvenCool™ Cryo Technology included in the new cryoballoon optimizes the
delivery of the coolant and improves physicians’ ability to treat a wide range of
patient anatomies.
(Draft physician quote for consideration) “Patients should feel confident that we are
using a proven technology with a strong safety profile, along with additional
therapeutic benefits. The next-generation Arctic Front provides greater treatment
efficiency, a real-world advantage that can positively impact our patients,” said
[insert name, title, affiliation].
Insert first implant patient information and additional physician comments on patient as
appropriate
Atrial fibrillation is one of the most common and undertreated heart rhythm
disorders in the world. Approximately [3 million Americans4/5 million
Europeans5] are estimated to have the disease. Half of all diagnosed patients fail
drug therapy,6 and if left untreated, patients have up to a five times higher risk of
stroke and an increased chance of developing heart failure.7 Additionally, since
atrial fibrillation is often age-related, as the [insert country affiliation] population
continues to grow older, the need for more effective treatment options is
escalating.
To date, the Arctic Front and Arctic Front Advance systems have been used to
successfully treat more than 70,000 patients in more than 700 medical centers in
40 countries.
###
Include photo of patient and doctor
Andrade JG, Khairy P, Guerra PG, et al. Efficacy and safety of cryoballoon ablation for
atrial fibrillation: a systematic review of published studies. Heart Rhythm. September
2011;8 (9):1444-1451.
2 Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with
antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and
meta-analyses. Circ Arrhythm Electrophysiol. August 2009;2(4):349-361.
3 Medtronic Inc., Arctic Front Cardiac CryoAblation Catheter clinical reports, in support
of FDA premarket approval.
4 CardioSmart. The American College of Cardiology. Retrieved from
http://cardiosmart.org/HeartDisease/CTT.aspx?id=222 on August 13, 2012.
5 CardioSmart. The American College of Cardiology. Retrieved from
http://cardiosmart.org/HeartDisease/CTT.aspx?id=222 on August 13, 2012.
6 JAMA 2001; 285:2370-5.
7 Fuster et al. Journal of the American College of Cardiology. 2006; 48:854-906.
1